The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
Open accessAbstract
OBJECTIVE: In addition to improve glucose intolerance, recent studies suggest that glucagon-like peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of this study was to evaluate the effect of GLP-1 receptor agonism on very-low-density lipoprotein (VLDL)-TG production and liver TG metabolism. EXPERIMENTAL APPROACH: The GLP-1 peptide analogues CNTO3649 and exendin-4 were continuously administered subcutaneously to high fat diet-fed APOE*3-Leiden transgenic mice. After 4 weeks, hepatic VLDL production, lipid content, and expression profiles of selected genes involved in lipid metabolism were determined. RESULTS: CNTO3649 and exendin-4 reduced fasting plasma glucose (up to -30% and -28% respectively) and insulin (-43% and -65% respectively). In addition, these agents reduced VLDL-TG production (-36% and -54% respectively) and VLDL-apoB production (-36% and -43% respectively), indicating reduced production of VLDL particles rather than reduced lipidation of apoB. Moreover, they markedly decreased hepatic content of TG (-39% and -55% respectively), cholesterol (-30% and -55% respectively), and phospholipids (-23% and -36% respectively), accompanied by down-regulation of expression of genes involved in hepatic lipogenesis (Srebp-1c, Fasn, Dgat1) and apoB synthesis (Apob). CONCLUSION: GLP-1 receptor agonism reduces VLDL production and hepatic steatosis in addition to an improvement of glycemic control. These data suggest that GLP-receptor agonists could reduce hepatic steatosis and ameliorate dyslipidemia in patients with type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent research conducted by Parlevliet et al. 55 substantiates this point while also revealing both DPP-1i (exendin-4) and GLP1-RA result in decreased hepatic lipogenesis among mice consuming high-fat diets.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They also discovered that treatment with GLP-1 suppresses the activity of genes participating in lipogenesis.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [55]
In the citing paper
“It has been proposed that GLP-1RA ameliorate hepatic steatosis by increasing fatty acid oxidation, enhancing very-low-density lipoprotein (VLDL) secretion and inhibiting lipogenesis [170,180].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 2×
“Hepatic lipid content Liver lipids were extracted according to a modified protocol from Bligh and Dyer [21].”
MethodMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both developed and developing countries, with impaired glucose tolerance and insulin resistance as hallmarks [1,2].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“However, therapeutic application of GLP-1 is hampered due to its short circulating halflife (,2 minutes), because it is rapidly degraded by dipeptidyl peptidase 4 (DPP-4) that is widely expressed in endothelium and intestinal mucosa [10].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Since uptake of TG from the diet eventually contributes to VLDL-TG production [37,38], reduced chylomicron production may contribute to the observed effect of GLP-1 receptor agonism on hepatic VLDL production.”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 1×
“Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both developed and developing countries, with impaired glucose tolerance and insulin resistance as hallmarks [1,2].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake [7], slowing gastric emptying [8], and inhibition of glucagon secretion [9].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“GLP-1 is an incretin hormone produced by intestinal L cells and the brain [4,5].”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“with earlier reports that GLP-1 and its analogs ameliorate wholebody glucose intolerance in obese animal models [23,24] and in T2DM patients [25].”
BackgroundSeparation of plasma lipoproteins by density-gradient ultracentrifugation
Redgrave, T. G., Roberts, D. C. K., & West, C. E. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90488-1 · Cited by 1,107 · cited 1×
“At 120 min, mice were euthanized, and blood was collected by orbital puncture for isolation of VLDL by density gradient ultracentrifugation [19].”
MethodKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 13×
“It is known that the contribution of de novo lipogenesis to total hepatic VLDL secretion strongly increases from 2–5% under healthy conditions up to 25– 30% in T2DM patients with hepatic steatosis [28,29].”
BackgroundInfluential
Cited by
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
“In high-fat dietfed ApoE*3-Leiden CETP-transgenic mice, GLP1-R agonist treatment decreased hepatic steatosis and plasma TG by respectively decreasing DNL and VLDL production [187].”
BackgroundAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Arguello, G., Balboa, E., Arrese, M., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306
Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism
Bruce, K. D., Zsombok, A., & Eckel, R. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00060 · Cited by 262
Metadata
- Authors
- Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., Pijl, H., & Rensen, P. C. N.
- Affiliations
- Leiden University Medical Center (NL)
- Janssen Research & Development (United States) (US)
- Netherlands Organisation for Applied Scientific Research (NL)
- Corresponding author
- Rensen, Patrick C. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-11-02
- Volume
- 7
- Issue
- 11
- Pages
- e49152
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3487842
- OpenAlex
- W2139855450
- Cited by
- 97
- References
- 45
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 2 · 2018: 5 · 2017: 13 · 2016: 5 · 2015: 8 · 2014: 11 · 2013: 5
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TNO Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor agonism, glucagon-like peptide-1, VLDL production, hepatic steatosis, hepatic lipogenesis, exendin-4, APOE*3-Leiden mice, high-fat diet, dyslipidemia, type 2 diabetes, hepatic triglyceride metabolism, apolipoprotein B, SREBP-1c, fatty acid synthase, insulin, glycemic control
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Apolipoproteins B, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Liver, Insulin, Liver, Male, Mice, Transgenic, Peptides, Venoms, Receptors, Glucagon, Lipogenesis, Dyslipidemias, Mice, Glucagon-Like Peptide 1, Apolipoprotein E3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0049152
- The paper
- Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., Pijl, H., & Rensen, P. C. N. (2012). GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0049152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.